Dupont Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Dupont Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34	Hold	1	–	–	﹤0.01%	34
2026 Q1	$32	Hold	1	–	–	﹤0.01%	94
2025 Q4	$35	Hold	1	–	–	﹤0.01%	96
2025 Q3	$28	Hold	1	–	–	﹤0.01%	101
2025 Q2	$18	Hold	1	–	–	﹤0.01%	102
2025 Q1	$20	Hold	1	–	–	﹤0.01%	103
2024 Q4	$26	Hold	1	–	–	﹤0.01%	104
2024 Q3	$17	Hold	1	–	–	﹤0.01%	121
2024 Q2	$19	Hold	1	–	–	﹤0.01%	131
2024 Q1	$24	Hold	1	–	–	﹤0.01%	145
2023 Q4	$11	Hold	1	–	–	﹤0.01%	152
2023 Q3	$9	Hold	1	–	–	﹤0.01%	221
2023 Q2	$12	Hold	1	–	–	﹤0.01%	621
2023 Q1	$13	Hold	1	–	–	﹤0.01%	738
2022 Q4	$11	Buy	+1	New	+$10	﹤0.01%	1409

Other funds holding NAMS

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Dupont Capital Management's NAMS Position: Q2 2026 in Review

Dupont Capital Management held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 1 share worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #34.

Dupont Capital Management first reported a position in NAMS in Q4 2022 and has held it in 15 quarters since. The position peaked at $35 in Q4 2025. 81 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Dupont Capital Management held 1 share of NewAmsterdam Pharma worth $34 as of Q2 2026.
Dupont Capital Management left its NewAmsterdam Pharma share count unchanged in Q2 2026.
NewAmsterdam Pharma made up ﹤0.01% of Dupont Capital Management's portfolio in Q2 2026, its #34 holding.
Dupont Capital Management first reported a position in NewAmsterdam Pharma in Q4 2022 and has held it in 15 quarters since.
Dupont Capital Management's NewAmsterdam Pharma position peaked at $35 in Q4 2025.
81 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Dupont Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.